ClinicalTrials.gg
Active, not recruitingNCT06011109Updated Oct 5, 2026

Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

A Phase 1/2 interventional study of APG-157 in Glioma and Glioblastoma Multiforme, sponsored by Aveta Biomics, Inc.. Active, not recruiting at 2 sites in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Primary conditionGlioblastomaRegistry: GliomaReclassifiedWhy we changed it
Registry
Glioma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glioblastoma
Why
  1. The study's listed conditions name Glioblastoma, a narrower term within Glioma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aveta Biomics, Inc. · Phase 1/2, Interventional, and Treatment

Updated Oct 5, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 323 under way, 16 of them phase 3. Glioblastoma · United States.

Planned enrollment
601st of 1,155
30 · median 33
Started
2023
with 57 others
Phase 1/2
190 of 1,302
32 open now
Primary completion
2026-12
later than 90 of 321 live
Registered
1,157th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 601st largest by planned enrollment of the 1,155 interventional ones that give a count, is one of 58 that started in 2023, is one of 190 in phase 1/2, reaches primary completion later than 90 of the 321 other live ones, and was the 1,157th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 340 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study aims to answer are:

  • Progression-free and overall survival of patients receiving this combination;
  • Quality of Life (QOL); and
  • Tumor response on imaging

The participants will take APG-157 daily by dissolving two pastilles in their mouth at around breakfast, lunch and dinner time (total of six pastilles per day). The pastilles dissolve in the mouth.

The participants will continue to receive Bevacizumab as standard of care.

Read the detailed description

The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma who have previously progressed on bevacizumab alone. The main questions the study aims to answer are:

  • Progression-free and overall survival of patients receiving this combination;
  • Quality of Life (QOL); and
  • Tumor response on imaging

Additional aims include:

  • characterization of pharmacokinetics (PK) of APG-157 in the presence of bevacizumab; and
  • optionally serum changes in VEGF and HIF-1 alpha, if the study shows preliminary indication of efficacy

The participants will take APG-157 daily by dissolving two pastilles in their mouth at around breakfast, lunch and dinner time (total of 6 pastilles per day). The pastilles dissolve in the mouth.

The participants will continue to receive Bevacizumab and be present for scheduled visits and examinations as standard of care.

03

Conditions studied

  • Glioma
  • Glioblastoma Multiforme

Browse trials for

Keywords

  • APG-157
  • Bevacizumab
04

In context

Glioblastoma Reclassified

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's planned enrollment of 30 is below the median of 36 across 1,756 interventional studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Aveta Biomics, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Compared within Glioblastoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glioma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have proven diagnosis of high grade (aka grade III or IV) glioma that has progressed on bevacizumab (anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma, gliosarcoma, H3K27M mutant glioma).
  2. Patients must have received prior radiation therapy and standard temozolomide. Patients who have received any number of therapies for previous progressions will be considered eligible.
  3. Patients must be three or more months from the end of chemoradiotherapy or have or imaging consistent with disease progression.
  4. Physiologic Status/Age: Patients must be 19 years of age or older (the age of consent in Nebraska.)
  5. Patients must have recovered from any toxicity of prior therapy to Grade 1 or less.
  6. Performance Status of 0-3.
  7. Patients must have an adequate bone marrow reserve (ANC count ≥1,500/mm3, > 8 g/dL, count ≥100,000/mm3).
  8. Patients must have adequate renal and hepatic function with:

    1. creatinine \< 1.5 x institutional (ULN).
    2. total \< 1.5 x ULN (unless due to Gilbert's disease)
    3. (AST) or alanine aminotransferase (ALT) \<2.5 x ULN
    4. serum alkaline phosphatase less than 2.5 times the upper limits of normal)
  9. The patient must willingly provide written, after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.
  10. Women of must be non-pregnant and non-nursing and must agree to employ an effective barrier method of throughout the study and for up to 6 months following treatment.
  11. Women of must have a negative pregnancy test within 7 days of initiating study. (Non-child bearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and/or both ovaries).

Exclusion criteria

Exclusion Criteria:

  1. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of oral APG-157, or put the study outcomes at undue risk
  2. Immunotherapy, chemotherapy, radiotherapy, or experimental therapy within one full cycle period before first dose of study drug (i.e., for lomustine 6 weeks, for temozolomide 4 weeks)
  3. Lactating or pregnant
  4. History of uncontrollable allergic reactions to bevacizumab
  5. Cardiovascular Disease Defined as follows:

    • Inadequately controlled hypertension (i.e., systolic blood pressure (SBP) > 160 mm Hg and/or diastolic blood pressure (DBP) > 90 mm Hg despite antihypertensive therapy)
    • History of cerebrovascular accident (CVA) within 6 months
    • Myocardial infarction or unstable angina within 6 months
  6. Evidence or history of bleeding diathesis (greater than normal risk of bleeding, i.e., Hereditary Hemorrhagic Telangiectasia type I or HHT-1) or coagulopathy in the absence of therapeutic anti-coagulation or any hemorrhage/bleeding event > Grade 3 within 4 weeks prior to registration. Note: Patients with full-dose anticoagulants are eligible provided the patient has been on a stable dose for at least 2 weeks
  7. Active wound, a serious or non-healing wound, an active ulcer or untreated bone fracture within the last two months.
  8. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess ≤ 6 months prior to registration.
  9. Major surgical procedure, open , or significant traumatic injury ≤ 28 days prior to registration
  10. Any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    APG-157

    The participants will receive APG-157 daily by taking two pastilles in their mouth at around breakfast, lunch and dinner time (total of six pastilles per day). The pastilles dissolve in the mouth. The participants will continue to receive Bevacizumab as standard of care.

    Drug: APG-157

Interventions

  • The participants will receive APG-157 daily; and continue to receive Bevacizumab as standard of care.

07

What researchers measure

Primary outcomes

  1. Progression-free Survival

    To evaluate progression-free survival of participants with recurrent high-grade glioma treated with APG-157 and Bevacizumab. Progression of the disease will be assessed using commonly used imaging modality such as Magnetic Resonance Imaging or CT scan.

    Time frame: From date of commencement of treatment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months

  2. Overall Survival

    To evaluate overall survival of participants with recurrent high-grade glioma treated with APG-157 and Bevacizumab

    Time frame: From date of commencement of treatment until the date of death from any cause. Duration of assessment will be 12 months from the date of commencement of the treatment.

Secondary outcomes

  1. QOL assessment (EORTC QLQ-C30)

    Descriptively examine quality of life (QOL) using EORTC QLQ-C30 (Organization for Research and Treatment in Cancer Quality of Life Questionnaire C30). EORTC QLQ-C30 is a standardized questionnaire that rates function, symptoms and health status from patient perspective using various questions on a scale of 1 - 4 where generally 1 is rated as normal or no issue (not at all) and 4 being the maximum adverse impact being experienced (very much).

    Time frame: Every 8 weeks; from date of commencement of treatment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months

  2. Radiographic studies MRI or CT of the brain

    To measure tumor size in response to treatment

    Time frame: Every 8 weeks; from date of commencement of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months

  3. Pharmacokinetics (PK) of APG-157

    Measure the amount of APG-157 components in the blood in the presence of bevacizumab

    Time frame: At three timepoints: at start of dosing; at end of cycle 1 (each cycle is 28 days); and at end of cycle 2 after start of dosing.

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Of 52 industry-sponsored phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 75. This study's planned 36 months is below that.

Counting every sponsor, half of 137 studies reached it within 66 months; a quarter within 45 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Aug 25, 2023
StartActual
Dec 13, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06011109
Lead sponsor
Aveta Biomics, Inc.
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
Dec 13, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Nicole Shonka, MD
principal investigator · University of Nebraska
Joon Uhm, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Curcumin/Polyphenols-containing Botanical Agent APG-157

Start the discussion